|
07 Nov 2023 |
Bloomsbury Genetic Therapies Announces First Patient Enrolled in Phase 1/2 HORACE Clinical Trial of Investigational Gene Therapy BGT-OTCD for the Treatment of Ornithine Transcarbamylase Deficiency (OTCD)
|
|
07 Nov 2023 |
AviadoBio Announces FDA IND Clearance and Fast Track Designation for AVB-101 for the Treatment of Frontotemporal Dementia with Progranulin (GRN) Mutations
|
|
06 Nov 2023 |
TILT Biotherapeutics Announces Positive Clinical Data on Lead Asset TILT-123 at Society for Immunotherapy of Cancer 2023
|
|
06 Nov 2023 |
CRISPR Therapeutics Announces Preclinical Data at the American Heart Association (AHA) Scientific Sessions 2023
|
|
05 Nov 2023 |
Adverum Biotechnologies Announces 3-Year Efficacy and Safety Results from the OPTIC Extension Study in Patients with Wet AMD at AAO 2023
|
|
04 Nov 2023 |
REGENXBIO Presents Positive One Year Data from Phase II ALTITUDE® Trial of ABBV-RGX-314 for Treatment of Diabetic Retinopathy Using Suprachoroidal Delivery
|
|
04 Nov 2023 |
InGeneron Announces Encouraging Results from Emory University’s 480-Patient Phase III Knee Osteoarthritis Trial
|
|
03 Nov 2023 |
Candel Therapeutics Announces Initial Positive Interim Data from Randomized Phase 2 Clinical Trial of CAN-2409 in Non-Metastatic Pancreatic Cancer
|
|
03 Nov 2023 |
Allogene Therapeutics Presents Preclinical Data on a Novel Allogeneic CAR T Product Candidate Targeting Claudin18.2 at the Society for Immunotherapy of Cancer Annual Meeting
|
|
03 Nov 2023 |
Actym to Present Preclinical Data on Clinical Candidate ACTM-838 at 38th SITC Annual Meeting
|
|
03 Nov 2023 |
MiNK Therapeutics Presents Clinical Activity and Long-Term Persistence of Allogeneic iNKT Cells in Solid Tumors at SITC 2023
|
|
02 Nov 2023 |
Huidagene Therapeutics announces first patient dosed in multinational phase 1/2 trial of HG004 for inherited blindness
|
|
02 Nov 2023 |
Silence Therapeutics Announces Positive Topline Results from Phase 1 Multiple Dose Study of Zerlasiran in Subjects with High Lipoprotein(a) and Stable Atherosclerotic Cardiovascular Disease
|
|
02 Nov 2023 |
4DMT Presents Positive Interim Data from Phase 1/2 AEROW Clinical Trial of Aerosolized 4D-710 for Cystic Fibrosis at 2023 NACFC
|
|
01 Nov 2023 |
Cellectis Presents Pre-Clinical Data on Multi-armored Allogeneic MUC1-CAR T-cells Targeting Triple-Negative Breast Cancer at the Society for Immunotherapy of Cancer (SITC) 38th Annual Meeting
|
|
01 Nov 2023 |
Cellectis Announces Strategic Collaboration and Investment Agreements with AstraZeneca
|
|
01 Nov 2023 |
Human Biome Announces Prediction of first-in class, Biosynthetic Microbiome Against Silent Pandemic of Antibiotic-Resistant Bacteria and Doses First Patients in Contextual FMT Study to validate it
|
|
01 Nov 2023 |
Be Biopharma Presents Preclinical Data Demonstrating Ex-Vivo Engineered B Cell Medicines Produce Highly Active and Sustained Levels of Antitumor Biologics
|
|
31 Oct 2023 |
GSK enters agreement to obtain exclusive license for JNJ-3989 to expand the development of bepirovirsen
|
|
31 Oct 2023 |
Chimeric Therapeutics announces FDA clearance of IND application for CHM 2101, a novel CDH17 CAR T cell therapy for advanced gastrointestinal cancers
|
|
31 Oct 2023 |
Roche announces EMBARK trial in Duchenne muscular dystrophy (DMD) did not reach primary endpoint, but shows positive efficacy outcomes on all timed functional key endpoints
|
|
31 Oct 2023 |
Sarepta Therapeutics Announces Topline Results from EMBARK, a Global Pivotal Study of ELEVIDYS Gene Therapy for Duchenne Muscular Dystrophy
|
|
30 Oct 2023 |
Prime Medicine Presents First-ever Prime Editing Data in Non-human Primates Demonstrating Highly Efficient Ability of Prime Editors to Precisely Correct Disease-causing Mutation of GSD1b
|
|
27 Oct 2023 |
First Clinical Results of ATA-100, a Gene Therapy for the Treatment of Limb-Girdle Muscular Dystrophy Type 2I/R9 (LGMD2I/R9), Presented at ESGCT
|
|
27 Oct 2023 |
TransCode Therapeutics Announces Prolonged Survival in Murine Models with Glioblastoma Treated with Its Lead Candidate, TTX-MC138
|
